PL2834243T3 - Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania - Google Patents

Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania

Info

Publication number
PL2834243T3
PL2834243T3 PL13710250T PL13710250T PL2834243T3 PL 2834243 T3 PL2834243 T3 PL 2834243T3 PL 13710250 T PL13710250 T PL 13710250T PL 13710250 T PL13710250 T PL 13710250T PL 2834243 T3 PL2834243 T3 PL 2834243T3
Authority
PL
Poland
Prior art keywords
pyrazolo
pyrimidine
compositions
methods
based compounds
Prior art date
Application number
PL13710250T
Other languages
English (en)
Polish (pl)
Inventor
Yingzhi Bi
Kenneth Gordon Carson
Giovanni Cianchetta
Michael Alan Green
Godwin KUMI
Alan Main
Yulian Zhang
Glenn Gregory ZIPP
Original Assignee
Lexicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.
Publication of PL2834243T3 publication Critical patent/PL2834243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL13710250T 2012-03-09 2013-03-05 Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania PL2834243T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
EP13710250.5A EP2834243B1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
PL2834243T3 true PL2834243T3 (pl) 2018-09-28

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13710250T PL2834243T3 (pl) 2012-03-09 2013-03-05 Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania

Country Status (25)

Country Link
US (3) US8946415B2 (enExample)
EP (1) EP2834243B1 (enExample)
JP (1) JP6418950B2 (enExample)
KR (1) KR101965025B1 (enExample)
CN (1) CN104302649B (enExample)
AR (1) AR090292A1 (enExample)
AU (1) AU2013230128B2 (enExample)
BR (1) BR112014022000A8 (enExample)
CA (1) CA2866143C (enExample)
DK (1) DK2834243T3 (enExample)
ES (1) ES2676224T3 (enExample)
HU (1) HUE038786T2 (enExample)
IL (1) IL234486A (enExample)
IN (1) IN2014DN07384A (enExample)
MX (2) MX381849B (enExample)
NZ (1) NZ630721A (enExample)
PL (1) PL2834243T3 (enExample)
PT (1) PT2834243T (enExample)
RU (1) RU2014140735A (enExample)
SG (1) SG11201405561RA (enExample)
TR (1) TR201808280T4 (enExample)
TW (1) TW201341386A (enExample)
UY (1) UY34668A (enExample)
WO (1) WO2013134228A1 (enExample)
ZA (1) ZA201406149B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102085121B1 (ko) 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
RU2014140735A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
MX2016009352A (es) * 2014-01-31 2016-10-13 Bristol Myers Squibb Co Inhibidores de quinasa a base de quinolina.
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
US20170239249A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
EP4420732A3 (en) * 2014-12-15 2024-11-27 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
HRP20240780T1 (hr) 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
KR102772574B1 (ko) 2015-07-21 2025-02-24 터닝 포인트 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
SG11201803605YA (en) * 2015-11-02 2018-05-30 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
BR112019008604A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
CN109937202B (zh) 2016-11-02 2022-12-30 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
MX385576B (es) * 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY205416A (en) 2017-07-28 2024-10-21 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
JP7321183B2 (ja) * 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド がんを治療するためのｔｒｋキナーゼ阻害物質としての、５－（２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－３－（１ｈ－ピラゾール－１－イル）ピラゾロ［１，５－ａ］ピリミジン誘導体及び関連する化合物
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
CN111362949B (zh) 2017-12-22 2021-12-21 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
CN111848622A (zh) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
EP3856743A4 (en) * 2018-09-27 2022-06-15 Fochon Pharmaceuticals, Ltd. SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
EP4138844A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
WO2021216441A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
TW202525819A (zh) * 2023-09-08 2025-07-01 加拿大商薩泰洛斯生物科學公司 Ａｐ２相關激酶１抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
SG196855A1 (en) * 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2523552B1 (en) * 2010-01-14 2015-05-13 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
ES2834093T3 (es) * 2011-07-21 2021-06-16 Sumitomo Dainippon Pharma Oncology Inc Inhibidores de proteína quinasa heterocíclicos
HUE036040T2 (hu) * 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
RU2014140735A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102085121B1 (ko) 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
JP2015509535A (ja) 2015-03-30
WO2013134228A1 (en) 2013-09-12
CN104302649A (zh) 2015-01-21
BR112014022000A8 (pt) 2021-06-15
EP2834243A1 (en) 2015-02-11
US20150183792A1 (en) 2015-07-02
AU2013230128A1 (en) 2014-09-25
AR090292A1 (es) 2014-11-05
JP6418950B2 (ja) 2018-11-07
MX2014010589A (es) 2014-09-18
KR20140138864A (ko) 2014-12-04
DK2834243T3 (en) 2018-07-23
RU2014140735A (ru) 2016-04-27
TW201341386A (zh) 2013-10-16
US20130253194A1 (en) 2013-09-26
UY34668A (es) 2013-10-31
CA2866143A1 (en) 2013-09-12
TR201808280T4 (tr) 2018-07-23
US9403832B2 (en) 2016-08-02
SG11201405561RA (en) 2014-10-30
MX345830B (es) 2017-02-17
IN2014DN07384A (enExample) 2015-04-24
US20170129896A1 (en) 2017-05-11
EP2834243B1 (en) 2018-04-25
KR101965025B1 (ko) 2019-04-02
MX381849B (es) 2025-03-13
US8946415B2 (en) 2015-02-03
PT2834243T (pt) 2018-08-01
AU2013230128B2 (en) 2017-08-17
HUE038786T2 (hu) 2018-11-28
CN104302649B (zh) 2017-06-23
IL234486A (en) 2016-10-31
NZ630721A (en) 2016-12-23
ZA201406149B (en) 2016-06-29
ES2676224T3 (es) 2018-07-17
HK1201257A1 (en) 2015-08-28
BR112014022000A2 (pt) 2017-06-20
CA2866143C (en) 2020-08-04

Similar Documents

Publication Publication Date Title
ZA201406149B (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
IL236075A (en) History of imidazo [2,1 – b] pyridazine as kinase inhibitors, preparations containing them and their use History of imidazo [2,1 – b] pyridazine as kinase inhibitors, preparations containing them and their uses
SG11201501292UA (en) Anxiolytic composition, formulation and method of use
PT3041475T (pt) Compostos baseados em pirazolo[1,5-a]pirimidina, composições compreendendo-os e métodos da sua utilização
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
EP2931723A4 (en) NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND LACTAMASE INHIBITORS
SG10201609940RA (en) Compounds and their methods of use
IL240877A0 (en) History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
IL239447B (en) Converted derivatives of tetrahydro[1,2,4]triazolo[alpha-3,4]pyrimidine-5-yl-benzyl and pharmaceutical preparations containing these derivatives
AP3908A (en) Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
LT2882753T (lt) Pemetreksedo ir jo lizino druskos gavimo būdas
EP2862571A4 (en) CAMPTOTHECIN COMPOUND, AND ITS MANUFACTURE AND USE
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
PT2920174T (pt) Compostos de pirazolo[3,4-d]pirimidina substituídos, preparação e utilização dos mesmos como ligantes recetores sigma
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201500865B (en) Process for the preparation of sitagliptin and intermediate compounds
AP3582A (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
AU2012905317A0 (en) Methods and Preparation and Use of Xanthorrhoeaceae Compositions
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same